Literature DB >> 29035828

The role of CIP2A in cancer: A review and update.

Saiedeh Razi Soofiyani1, Mohammad Saeid Hejazi2, Behzad Baradaran3.   

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a characterized human oncoprotein that is able to promote cancer cells proliferation, anchorage-independent cell growth and resistance to apoptosis. CIP2A inactivates protein phosphatase 2A (PP2A) which down-regulates Akt (Protein Kinase B) phosphorylation and stabilizes c-Myc (c-Myc oncogene product) in cancer cells. CIP2A has been studied in the most of human malignancies. Here we discuss the role of CIP2A in cancer and give a summary of CIP2A expression in malignancies. Also, where available we indicated the association of CIP2A with the stage of cancers and patients prognosis, explain its localization and the possibility of targeting CIP2A in different cancers.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CIP2A; Cancer; Oncoprotein; PP2A; c-Myc

Mesh：

Substances：

Year:  2017        PMID： 29035828     DOI： 10.1016/j.biopha.2017.08.146

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  13 in total

1.  Oct4 facilitates chondrogenic differentiation of mesenchymal stem cells by mediating CIP2A expression.

Authors:  Lexiang Li; Qiwei Fu; Jiahua Shao; Bo Wang; Zheru Ding; Shuai Yuan; Jinhui Peng; Wei Xin; Jun Zhu; Yi Chen
Journal:  Cell Tissue Res       Date:  2022-04-18       Impact factor: 5.249

2.  Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype.

Authors:  Anna N Cvrljevic; Umar Butt; Kaisa Huhtinen; Tove J Grönroos; Camilla Böckelman; Heini Lassus; Ralf Butzow; Caj Haglund; Katja Kaipio; Tiina Arsiola; Teemu D Laajala; Denise C Connolly; Ari Ristimäki; Olli Carpen; Jeroen Pouwels; Jukka Westermarck
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

3.  CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.

Authors:  S Denk; S Schmidt; Y Schurr; G Schwarz; F Schote; M Diefenbacher; C Armendariz; F Dejure; M Eilers; Armin Wiegering
Journal:  Int J Colorectal Dis       Date:  2020-10-19       Impact factor: 2.571

Review 4.  PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.

Authors:  Henan Zhao; Duojiao Li; Baojing Zhang; Yan Qi; Yunpeng Diao; Yuhong Zhen; Xiaohong Shu
Journal:  Molecules       Date:  2017-12-20       Impact factor: 4.411

Review 5.  Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.

Authors:  Andrew R Clark; Michael Ohlmeyer
Journal:  Pharmacol Ther       Date:  2019-06-01       Impact factor: 12.310

6.  Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer.

Authors:  Jiang Yin; Danyang Chen; Kai Luo; Minying Lu; Yixue Gu; Shanshan Zeng; Xiangzhou Chen; Ying Song; Zhijie Zhang; Guopei Zheng; Zhimin He; Hao Liu
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

7.  Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.

Authors:  Wei Chen; Jing-Lin Liang; Kai Zhou; Qing-Li Zeng; Jun-Wen Ye; Mei-Jin Huang
Journal:  Cell Commun Signal       Date:  2020-04-22       Impact factor: 5.712

8.  siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells.

Authors:  Saiedeh Razi Soofiyani; Akbar Mohammad Hoseini; Ali Mohammadi; Vahid Khaze Shahgoli; Behzad Baradaran; Mohammad Saeid Hejazi
Journal:  Adv Pharm Bull       Date:  2017-12-31

Review 9.  Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.

Authors:  Cassandra P Nader; Aylin Cidem; Nicole M Verrills; Alaina J Ammit
Journal:  Respir Res       Date:  2019-10-17

10.  Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.

Authors:  Rajab Alzahrani; Amani A Alrehaili; Amal F Gharib; Farah Anjum; Khadiga A Ismail; Wael H Elsawy
Journal:  J Cancer Prev       Date:  2020-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.